CARDIOVASCULAR LABS’ DEVELOPMENT. THE VIEW FROM THE MEDTECH INDUSTRY
After many years with minimal structural change, the health care environment is in a phase of organizational and expectation adjustment.
Change in healthcare over the last 20 years was mainly driven by innovations. Pharmaceutical and technological solutions drove many of the changes in healthcare delivery. Many new treatment opportunities have been created for patients through the strong and fruitful collaboration between doctors and the industry. Many new products and pharmaceutical agents have been developed through these connections between industry and health care professionals. This has led to substantial improvements in patient care over the last years.
This journey is not finished and will continue. Many new therapies will be introduced over the next years. The healthcare systems however have more and more difficulty paying for these necessary innovations. The core issue is that cost and value/benefit are disconnected in healthcare reimbursement.
This leads to a cost focus by payers and policy makers.
The only way we can assure that patients can continue to benefit from innovations in the future is to restore the connection between cost and value, therefore we are actively pursuing the model of “Value Based Healthcare”. A model where payments will not occur on the basis of volume and production (fee for service) but payments should be connected to patient outcomes.
Besides this opportunity there is another aspect of healthcare spend we need to tackle. The use of infrastructure and human resources in healthcare is suboptimal. We can save lots of cost and energy if we organize the work environment smarter and more patient-centric.
We have seen enormous improvements in employee engagement if we help to organize Cathlabs differently, help the material management and work on patient flow and logistics. Medical staff will be able to spend more quality time on patient care and less on dealing with inefficiencies and internal challenges.
We believe that we , as a medical device company, can and should play a major role in facilitating a more efficient organized, outcome oriented, patient centric care model. We have the relationships with the physicians and nurses that allow us to build on that trust to facilitate change.
We believe that there is actually enough money in the socialized healthcare systems of the western world to provide optimal care to all citizens including the growing elderly population. In the emerging markets we should try to leap frog into innovative care and payment models to avoid creating big and rigid legacy systems that cannot be easily adapted.
The coming years will be fascinating, we will see major changes in the health care delivery models that will provide more appropriate and better care to patients.
Finally the industrial revolution will touch the way we provide healthcare.